Condition: Breast Cancer · Sponsor: Angela Toss
This study is an observational study being carried out in several hospitals. No extra tests or procedures are required beyond those already part of normal medical care. The study is sponsored by the University of Modena and Reggio Emilia and aims to include about 100 patients. The main goal of the study is to better understand the different biological types of breast cancer in patients who have hormone receptor-positive (HR-positive), HER2-negative breast cancer related to BRCA gene mutations. In particular, the study will explore whether these cancers tend to belong to molecular types that may respond less to endocrine or CDK4/6 inhibitor therapy. The study also compares cancers linked to BRCA1 and BRCA2 mutations and investigates whether the different biological types are associated with differences in disease outcomes and response to treatment.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Ospedale San Martino di Genova | Genova, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori Milano | Milan, Italy | Recruiting |
| Istituto Oncologico Europeo di Milano | Milan, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria Policlinico di Modena | Modena, Italy | Recruiting |
| Istituto Oncologico Veneto IRCCS Padova | Padova, Italy | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli di Roma | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07617025